Patricia Cortazar, MD

Articles by Patricia Cortazar, MD

Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives

ByLaleh Amiri-Kordestani, MD,Julia A. Beaver, MD,Patricia Cortazar, MD

November 16th 2015

This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

Latest Updated Articles

Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives
November 16th 2015

Patricia Cortazar, MD

Articles by Patricia Cortazar, MD

Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives

Latest Updated Articles

Trending on CancerNetwork

ASCO Releases New Patient-Clinician Communication Guidelines

Melanoma Vaccine Receives FDA Fast Track Designation

NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype

TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML

Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial